Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
This study has been completed.
Study NCT00021697 Information provided by Avanir Pharmaceuticals
First Received on August 1, 2001. Last Updated on August 4, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Amyotrophic Lateral Sclerosis
Additional conditions recognized in this trial
Motor Neuron Disease
Sclerosis
More general conditions related to this trial
Central Nervous System Diseases
Metabolic Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neuromuscular Diseases
Pathologic Processes
Proteostasis Deficiencies
Spinal Cord Diseases
TDP-43 Proteinopathies
Interventions listed in this trial
AVP-923
Additional drug interventions recognized in this trial
Dextromethorphan
Quinidine
More general drug interventions related to this trial
Adrenergic Agents
Adrenergic alpha-Antagonists
Adrenergic Antagonists
Anti-Arrhythmia Agents
Anti-Infective Agents
Antimalarials
Antiparasitic Agents
Antiprotozoal Agents
Antitussive Agents
Cardiovascular Agents
Central Nervous System Agents
Cholinergic Agents
Cholinergic Antagonists
Enzyme Inhibitors
Excitatory Amino Acid Agents
Excitatory Amino Acid Antagonists
Molecular Mechanisms of Pharmacological Action
Muscarinic Antagonists
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Respiratory System Agents
Therapeutic Uses
Sponsors listed in this trial
Avanir Pharmaceuticals
Back to top of Main Content
